Retrospective cohort study compares mortality and outcomes in septic patients treated with MB or HC, highlighting implications for treatment strategies.
Key Points
This research aims to evaluate the clinical outcomes of septics treated with methylene blue or hydroxocobalamin.
Retrospective cohort study using TriNetX network across 65 health systems.
Inclusion of adults with septic conditions hospitalized between 2016-2025; exclusion of specific complications.
Propensity score matching (1:1) applied to analyze 732 patients receiving MB or HC.
No significant difference in mortality at 3-7 days (9.8% for MB vs 12.6% for HC, p=0.241) or at 7 days (29.5% for MB vs 35.0% for HC, p=0.114).
Higher CRRT initiation observed with HC compared to MB (10.5% vs 3.3% and 29.0% vs 16.9%, both p<0.001).
Transient differences favored MB for reduced stroke rates (3.0% vs 0.0%, p=0.002) and lower ongoing vasopressor use at early time points (51.1% vs 39.1%, p=0.001).